• New formulation delivers up to 2,708% more CBD into bloodstream*
• Human clinical hypertension study HYPER-H21-1 also progressing

KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH 2.0″ cannabidiol (“CBD”) formulations in its second 2021 applied research and development study program, HYPER-A21-2.

1. AUC: Area Under the Curve, or total CBD delivery into the rodent bloodstream
2. 60-minute study duration
3. 60-minute study duration evaluated in 2019
4. 120-minute study duration evaluated in 2021

Lexaria continues to build a robust body of evidence demonstrating that its patented DehydraTECH technology can significantly enhance the delivery of lipophilic active ingredients such as CBD across a range of uptake levels, with ultimate applications to wide ranging areas including consumer packaged goods as well as drugs with potential for disease treatment applications.

In each arm of the study, ten male Sprague-Dawley rats were dosed orally at a level of 25 mg/Kg CBD, and over the next 120 minutes multiple measurements were taken to assess delivery into the bloodstream and tissues comparing the DehydraTECH formulations to certain controls. There were a total of 120 animals for the new DehydraTECH 2.0 formulations evaluated in studies HYPER-A21-1 and HYPER-A21-2. Both studies HYPER-A21-1 and HYPER-A21-2 were conducted by an independent, premier animal testing laboratory located in the United States.

Lexaria also confirms that its HYPER-H21-1 human clinical hypertension study is currently underway and dosing is nearly complete, utilizing a formulation most closely resembling the original 2019 DehydraTECH 2.0. Along with a more than a 3-fold increase in dose quantity, these formulation improvements are expected to be more effective than the original DehydraTECH 1.0 formulation used in Lexaria’s foundational 2018 human clinical study that nonetheless evidenced significant blood pressure reduction, as published and available at PubMed. Lexaria thus expects improved pharmacokinetic performance in its current human clinical study to translate into further improved pharmacodynamic performance. Lexaria will provide details on the outcomes of study HYPER-H21-1 when they become available.

* Compared with control formula utilizing medium chain triglycerides (coconut oil) representative of standard industry practices

About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:
[email protected]
Phone: 866-221-3341

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH technology that enhances qualities and uptake of all sorts of lipophilic (fat-based) molecules. As such, companies from diverse businesses have partnered with Lexaria recently, including Hill Street Beverage last week.

So What’s the Big Deal with DehydraTECH?

The human body has a natural digestive process that is quite proficient at filtering molecules to ensure safe delivery of only beneficial substances. In scientific nomenclature, a molecule (an oral medicine for example) actually reaching the human bloodstream is referred to as “bioavailability” and it can be a real challenge to do so.

Click on the Video for Education on Lexaria’s DehydraTECH technology.

DehydraTECH is an efficient Trojan horse for getting molecules delivered in oral form around the filtering process of liver metabolism and into the bloodstream. Lexaria accomplishes this by joining the payload – albeit a vitamin, active pharmaceutical ingredient, nicotine, cannabinoid, etc. – with a microscopic particle of a special type of fat known as LCFA’s (long chain fatty acids). Upon ingestion, the body detects the LCFA, not the molecule hidden alongside. There are a multitude of positive results from this technology, which have been verified through lab and human studies.

Click Here to View Lexaria’s Investor Presentation

For starters, many beneficial molecules taste and smell horrible. DehydraTECH eliminates that problem, making them palatable without using sugar like most competitors do today. Even more importantly, the bioavailability profile changes dramatically. The time it takes to feel the effect can be shaved to as little as 10 minutes (as little as 2 minutes in animal testing) from the natural metabolic process that typically takes around 90 minutes. Furthermore, bioavailability can surge as much as 10-fold, meaning the consumer is getting more of what they want and need faster.

Opportunities Abound

The beauty of the DehydraTECH technology is that it is easily and cost-effectively implemented into existing manufacturing operations. It appeals to a diverse group of customers because of the many different types of molecules for endless applications. As detailed in the company’s presentation, from pills to coffee, DehydraTECH is a highly versatile drug delivery method.

Some of the initial targets being focused on are cannabinoids, NSAIDs such as ibuprofen (non-steroidal anti-inflammatory drugs), vitamins and nicotine. The opportunity to genuinely disrupt the nearly $1 trillion market with the world’s first ingestible nicotine product did not escape Marlboro owner Altria (NYSE: MO). In January, the international tobacco behemoth agreed to put up $12 million for R&D and product development for oral, reduced risk nicotine consumer products using DehydraTECH and agreed to pay Lexaria a royalty on products sold with DehydraTECH technology.

July Big Month for New Partners

The cannabis market is booming, as more health conscious consumers look to the plant for all of its therapeutic effects. In particular, people are looking to cannabidiol (CBD), a prominent cannabinoid found in hemp and cannabis trumpeted for its benefits for treating everything from dry skin to epileptic seizures.

The legalization of hemp at the start of the year thanks to the passage of the U.S. Farm Bill has the hemp market abuzz and Lexaria is in the thick of it. Early in July, the company’s subsidiary Lexaria Hemp Corp. entered a 5-year agreement to provide DehydraTECH technology to Nic’s Beverages Ltd for use in CBD-based beverages to be produced and sold throughout America.

Nic’s is the fourth company (3 in the U.S. and 1 in Canada) to license the technology for beverages. Nic’s plan is to begin making ready-to-drink cold brew coffees enhanced with CBD from multi-spectrum hemp oil.

“DehydraTECH technology is perfect in allowing us to deliver CBD from hemp oil with zero impact on our cold brewed coffee’s outstanding aroma or flavor,” commented Nic’s CEO John Goodpasture.

A day after the Nic’s deal was disclosed, Lexaria said it inked a 5-year deal to provide DehydraTECH to B2B manufacturing company Universal Hemp LLC. Universal Hemp will be using the technology for its hemp-derived CBD bulk ingredients it supplies to the nutraceutical and consumer packaged goods industries throughout the U.S. and Canada.

“In terms of bioavailability, shelf stability and taste, [DehydraTECH] is the best performing technology in the market, hands down,” said Chad Kahunahana, CEO and Founder of Universal Hemp about the partnership.

Future royalties and other financial terms were kept confidential, but it was revealed that the deal has minimum down payments over the life of the contract of US$3.75 million.

Lexaria kept the momentum going all month, announcing a 10-year joint manufacturing partnership (JMP) with Hill Street Beverage Co. (TSX-V: BEER) to create commercial products utilizing DehydraTECH. Per the pact, the companies will work together to make THC cannabis and/or CBD hemp powder for all new (and yet unnamed) consumer products in the form of tablets, capsules and packets.

Click Here to View Lexaria’s Investor Presentation

The JMP will also produce similar powders as a bulk ingredient for manufacturing processes for sale to other licensed producers seeking to use Lexaria’s advanced infusion technologies to create their own wide variety of products for sale within Canada.

Hill Street is in the midst of completing the acquisition of OneLeaf Cannabis. Manufacturing of the new goods, which will be handled by Hill Street and utilize DehydraTECH in the process, is expected to be done at OneLeaf’s cultivation and processing facility in Regina, Saskatchewan, pending all Health Canada approvals.

For its part in bringing DehydraTECH to the table, Lexaria is entitled to 50% of the new company’s profits.

The companies are making the moves now to be properly positioned when cannabis-infused edibles become legal throughout Canada later this year.

The JMP may be new, but the relationship between Hill Street and Lexaria is not. Hill Street had previously licensed the DehydraTECH technology for CBD-infused beverage sales in Canada. Last week, a new 10-year agreement was forged giving Hill Street global rights on a semi-exclusive basis.

It seems that CEO’s of consumer product companies are enamored with DehydraTECH: “Lexaria has proven themselves time and again to be the ideal infusion platform for our products,” commented Hill Street’s Chairman and CEO, Terry Donnelly.

Under the terms of the agreement, Hill Street is paying Lexaria US$1.8 million in BEER stock, most up front, with the remainder owed upon meeting milestones for entering new international markets.

Lexaria announced in August that they’ve received a cannabis R&D license from Health Canada that does not expire until August 2023, allowing the company for the first time ever to place its state-of-the-art laboratory into operation and accelerate a truly impressive research program.

“Lexaria has evolved so rapidly and achieved so much in the past eight months, that we are nearly unrecognizable compared to the end of 2018,” said Chris Bunka, Chief Executive Officer of Lexaria. “We’re signing new customers at ten times the rate of previous years; we’ve partnered with one of the largest companies in North America; additionally, we’ve just completed construction of one of the most advanced labs in the industry. 2019 has been a fabulous year so far and we think it will only get better, and drive strong new revenues and advances into 2020 and far beyond.”

The most recent sign of those advances is the appointment of Mr. Brian Quigley to their board of directors. Mr. Quigley most recently spent 16 years at Altria Group, 7 of those years were spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company. It was during that period of time that the existing business relationship between Altria and Lexaria was negotiated.

“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.”

Consumer Products Company? Licensing Company? Try Both.

Because Lexaria has two brands of its own: ViPova (a beverage lineup of teas and coffee) and both TurboCBD capsules and ChrgD+ powdered drink mix, they sometimes get lumped in with other CBD consumer brands companies. Adding in the new venture with Hill Street adds to that assumption.

Fact is though, technology licensing is at the core of Lexaria’s business. Candidly, it is a far more lucrative business too, with margins generally 90+%. With a robust patent estate of about a dozen issued patents and more than 60 additional pending, management has built itself a strong position with a better solution than sweeteners and chemicals for any and all ingestible products by merely adding one step to the manufacturing process.

When more companies continue to learn that they can add DeyhydraTECH to their operations to make lipophilic compounds palatable with superior bioavailability for only a fraction of a penny per product serving, there is likely going to be more companies knocking on Lexaria’s door.

Click Here to View Lexaria’s Investor Presentation

Click Here For More Information on Lexaria Bioscience Corp.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ash Stringer